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Letter to the Editor
Stool for fecal microbiota transplantation
should be classified as a transplant
product and not as a drug
Josbert J Keller1,2, Maria JGT Vehreschild3, Christian L Hvas4,
Simon MD Jørgensen4 , Jouzas Kupciskas5, Alexander Link6, Chris JJ Mulder7,
Simon D Goldenberg8, Ramesh Arasaradnam9 , Harry Sokol10,11,12,
Antonio Gasbarrini13, Christoph Hoegenauer14, Elizabeth M Terveer15,2,
Ed J Kuijper16,2 and Perttu Arkkila17; On behalf of the UEG working group
of the Standards and Guidelines initiative Stool banking for FMT
Fecal microbiota transplantation (FMT) or donor feces
infusion is a therapy that aims to restore a perturbed
gut microbiota composition and function. FMT is
eﬀective for treatment of patients with (multiple) recur-
rent Clostridioides diﬃcile infections1–3 and recom-
mended by current guidelines.4–6 In the near future,
FMT may also become an accepted treatment option
for other intestinal or extra-intestinal diseases.7
FMT is performed using suspensions made of donor
stool from carefully selected and screened healthy indi-
viduals.1,7 Donor screening is time consuming and
costly. Before the establishment of stool banks, phys-
icians and patients had to ﬁnd their own donors. This
resulted in uncontrolled application of FMT, and the
logistical challenge made physicians reluctant to oﬀer
FMT to their patients. To overcome these problems,
stool banks have been established.8,9 The mission of
those stool banks is:
(i) to produce ready-to-use donor feces suspensions
for treatment of patients,
(ii) to improve the quality and safety of FMT by cen-
tralization and standardization,
(iii) to increase the cost eﬀectiveness of FMT, and
(iv) to facilitate research.
Stool banks are built in concordance with the model
of blood banks and should follow quality standards
applied to other transplantation products. Most stool
banks are non-proﬁt institutions, operating at a local
(institution-based), national or international level.
Recently, a UEG-funded working group was initiated
to deﬁne quality standards for stool banking and FMT,
which will result in further standardization of this new
treatment approach. The current costs to deliver a
ready-to-use stool suspension are E1050–1700 in
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Europe.9,10 There are also commercial initiatives,11
which may aim for much higher prices.
Driven by the needs of patients, stool banks have
emerged as new entities in a landscape without existing
regulatory boundaries. This lack of guidance and
National or European legislation may become a serious
threat to providing the treatment for severely ill patients.
This is also illustrated by the recent safety alert in the US
about the transmission of multi-drug resistant organ-
isms through FMT,12 which underlines the need for
standardization, quality assurance, and a regulatory
framework supporting the activities of stool banks.
Legislation requires classiﬁcation of stool as a product
to treat patients.We strongly believe that stool should be
considered a transplant product, or be regarded equiva-
lent in status to blood products used for transplantation
or transfusion purposes. The EU Tissue and Cells
Directive (2004/23/EC) is best suited to guide FMT.
Currently, this Directive does not cover FMT because
the mechanism of action is not mediated by human cells.
An adjustment to align this directive with the new reality
of fecal transplantation is thus urgently needed. Only in
the case of modiﬁcation to the donated feces, other than
those necessary for the conservation of the microbial
community, does the product made of the donated
feces become comparable to a drug and is best covered
within the European directive for medicinal products
intended for human use (2001/83/EC).
Unfortunately, the misclassiﬁcation of donor feces
suspensions as a drug or pharmaceutical product,
although diﬃcult to imagine, is still one of the possible
outcomes of the current discussion about classiﬁcation.
Currently, stool has already been classiﬁed as a drug in
countries such as France, Germany, and the United
Kingdom. Recently, companies have formed the
‘‘Pharmabiotic Research Institute’’ in Europe and the
‘‘Microbiome Therapeutics Innovation Group
(MTIG)’’ in the US. The mission of those groups is
‘‘to improve market access,’’ and to ‘‘enhance the regu-
latory, investment, and commercial environment for
microbiome therapeutic drug product development.’’
Both groups have published statements about the clas-
siﬁcation of FMT as a drug.13,14 MTIG actively collab-
orates with the Food and Drug Administration for the
evaluation of safety parameters related to microbiota-
based therapeutic products. Concern has been raised by
the MTIG that the existence and accessibility of mater-
ial from stool banks limits enrollment into clinical trials
for microbiome therapeutics. This illustrates how com-
panies are active to inﬂuence the current discussion
about classiﬁcation and regulation of FMT. In fact,
this discussion has already been troubled by commer-
cial interest in the US some years ago.15
In this regard, it is important to mention the overall
major disadvantages of classiﬁcation as a drug, which
will result in time-consuming and costly registration
processes, and a sharp and unjustiﬁed rise in costs.
Most importantly, this will negatively impact availabil-
ity and innovation, obstructing, for example, the future
development of single-donor individualized solutions
due to the requirements for standardization of active
substances. We postulate that stool treatment deﬁned
as drug treatment is counterproductive. Stool is not a
standardized product that is produced in a factory, but
a highly diverse and donor-speciﬁc substance of human
origin (SoHO) delivered by healthy, usually unpaid,
volunteer donors. Therefore, stool suspensions require
suitable guidance of quality and safety measures com-
parable to guidance of other SoHO (blood, tissues, cells
and organs) within the EU.
If government authorities seek aﬀordable and qual-
ity-assured FMT, a supportive regulatory framework,
in combination with appropriate funding or reimburse-
ment, is required for stool banks. This will not only
guarantee broad access and safety of FMT, but also
enable the future innovation of this new treatment
strategy targeting the gut microbiota. If eventually
future research results in the replacement of FMT by
standardized mixtures of bacteria (or another yet undis-
covered stool extract that could theoretically underly
the clinical eﬀects of FMT), these should indeed be
regulated as a drug or pharmaceutical product.
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